HYPERION THERAPEUTICS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY14 | FY13 | FY12 | FY11 | |
|---|---|---|---|---|
| Revenue | $113.6M | $42.2M | $286,000 | — |
| Operating income | −$4.2M | −$13.4M | −$28.5M | −$26.2M |
| Net income | −$6.3M | $16.6M | −$32.3M | −$29.4M |
| Total assets | $180.4M | $142.5M | $51.2M | $8.1M |
| Total liabilities | $48.9M | $22.8M | $16.8M | $31.9M |
| Equity | $131.6M | $119.7M | $34.4M | −$82.1M |
| EPS (diluted) | $0.06 | $-0.52 | $-4.45 | $-62.68 |
| Shares out. | 20.2M | 16.6M | 16.6M | 469,319 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2014- Operating margin
- −3.7%
- Net margin
- −5.5%
- Return on equity
- −4.8%
- Return on assets
- −3.5%
- Return on capital (ROCE)
- −2.8%
- Liabilities / assets
- 27.1%
- Debt / equity
- 0.37×
- Book value / share
- $6.52
- Revenue growth (YoY)
- 169.1%
- Net income growth (YoY)
- −137.6%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2014- Altman Z″ (distress)
- 5.04safe
- Accruals / assets
- −20.6%clean
- Beneish M-Score
- -2.11normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 warning● 5 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMay 7, 2015
- Results of operationsApr 9, 2015
- Entered a material agreement · Other material eventMar 30, 2015
- Results of operationsFeb 26, 2015
- Entered a material agreementFeb 17, 2015
- Director / officer changeFeb 10, 2015
- Results of operations · Director / officer changeNov 6, 2014
- Material impairment · Other material eventSep 8, 2014
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ACONSONANCE CAPITAL MANAGEMENT LPFeb 11, 2016
- CT ORDERJun 1, 2015
- 15-12BMay 18, 2015
- SC 13D/AFORM SC 13D/AMay 15, 2015
- UPLOADMay 14, 2015
- SC 13D/AHYPERION THERAPEUTICS, INC. #2May 11, 2015
- 4May 11, 2015
- 4May 11, 2015
- 4May 11, 2015
- 4May 11, 2015
- 4May 11, 2015
- 4May 11, 2015
- 4May 11, 2015
- 4May 11, 2015
- 4May 11, 2015
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.